BD-Tau
Advancing Biomarker Research in Neurodegenerative Diseases
Simoa® BD-Tau Advantage PLUS Assay (Item 104797)
The Simoa® BD-Tau Advantage PLUS Assay advances neurodegenerative research with its ultrasensitive and selective measurement of brain-derived tau (BD-Tau) levels in serum, plasma and cerebrospinal fluid (CSF) samples. This assay is a powerful tool for furthering translational and clinical research in Alzheimer’s Disease (AD) and other neurodegenerative conditions.Key Features of the Simoa® BD-Tau Advantage PLUS Assay
- Pioneering Integrated BD-Tau Assay Solution: Discover new insights with this emerging and differentiating biomarker.
- Ultra-Sensitive Protein Measurement: Quantify BD-Tau in blood at sub-picogram levels.
- Efficiency Through Automation on HD-X Platform: Experience a streamlined and scalable workflow with full automation.
- Enhanced Precision with Simoa® Advantage PLUS: Ensure reliable results for large and longitudinal studies.
Data Sheet
Certificates of Analysis
Understanding the Significance of BD-Tau in Alzheimer’s Research
Tau is a microtubule-stabilizing protein predominantly found in the central nervous system (CNS), but also present in peripheral tissues. While CSF T-Tau is a well-established diagnostic biomarker for AD, its performance as a blood-based biomarker is limited. Given that about 80% of Tau in blood originates from peripheral tissues, there is a critical need to selectively measure CNS-originated Tau, referred to as brain-derived Tau (BD-Tau). This selective measurement of BD-Tau enhances the specificity and accessibility of Tau as a biomarker for AD.
BD-Tau is comprised mainly of low molecular weight (M.W.) isoforms, which lack the large peptide insert from exon 4a found in peripheral tissue Tau isoforms. By selectively measuring these low M.W. Tau isoforms in circulation, BD-tau demonstrates excellent correlation with CSF T-Tau and holds unique potential in identifying AD-type neurodegeneration. Moreover, BD-Tau may aid in monitoring recovery following severe traumatic brain injury (sTBI) and ischemic stroke.
Applications and Intended Use
The Simoa® BD-Tau Advantage PLUS is a digital immunoassay intended for the measurement of BD-Tau in human plasma, serum, and CSF samples, facilitating research in neurodegenerative diseases.
Assay Specifications
- Compatible instruments: HD-X
- Analytical Lower Limit of Quantification (LLOQ): 0.133 pg/mL
- Lower Limit of Detection (LOD): 0.044 pg/mL
- Dynamic range: 0-600 pg/mL for serum/EDTA plasma; 0-15 ng/mL for CSF
Kit Contents
The assay kit includes all necessary reagents and controls to perform 96 tests.
Related Resources
Flyer: Unlock New Insights with Selective Measurement of BD-Tau
FAQ
Q: How does the BD-Tau Assay improve specificity in tau measurement?
A: The assay selectively measures CNS-originated Tau, reducing interference from peripheral tissue Tau.
Q: Can the BD-Tau Assay be used for longitudinal studies?
A: Yes, it ensures reliable results for both large-scale and longitudinal studies.